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Abstract
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Background—Elderly individuals (age >65 years) with cancer are at high risk for newly
diagnosed depression after a cancer diagnosis. It is not known whether the risk of newly diagnosed
depression varies by cancer type.
Purpose—To examine the variations in the risk of newly diagnosed depression by cancer type
among elderly individuals with cancer.
Methods—This study used a retrospective cohort study design and data from the linked SEERMedicare files. Elderly individuals (age >65 years) with incident breast, colorectal (CRC), and
prostate cancers diagnosed between 2007 and 2011 (N=53,821) were followed for 12 months after
cancer diagnosis. Depression diagnosis was identified during the 12-month follow-up period after
cancer diagnosis using the ICD-9-Clinical Modification. Complementary log–log regression was
used to examine the association between cancer type and risk of newly diagnosed depression after
adjusting for other risk factors for depression.
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Results—We found a significantly higher percentage of newly diagnosed depression among
women with CRC compared with those with breast cancer (5.8% vs 3.9%), and among men with
CRC compared with those with prostate cancer (3.4% vs 1.6%). In the adjusted analysis, women
with CRC had a 28.0% higher risk of newly diagnosed depression compared with women with
breast cancer (adjusted risk ratio [ARR], 1.28; 95% CI, 1.12–1.46) and men with CRC had a
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104.0% higher risk of newly diagnosed depression compared with those with prostate cancer
(ARR, 2.04; 95% CI, 1.65–2.51).
Conclusions—Our findings identified cancer types associated with a high risk of newly
diagnosed depression after cancer diagnosis, who might benefit from routine depression screening
to help in its early detection and treatment.

Background

Author Manuscript

Depression is a highly prevalent mental health condition among elderly cancer survivors
(age >65 years). According to the CDC, “cancer survivor refers to a person who has been
diagnosed with cancer, from the time of diagnosis throughout his or her life.”1 Cancer
survivors often find the diagnosis of cancer to be a very stressful life event. They may face a
fear of death; changes in physical health, life plans, work, and social roles; and some
financial concerns.2 As a result, some cancer survivors may have difficulties adjusting to the
diagnosis of cancer and may develop psychological side effects. Evidence from the literature
suggests that the psychological effects of cancer diagnosis may range from sadness to
depressive symptoms to clinical depression, hereinafter referred to as “depression.”3
Depression is highly prevalent among cancer survivors compared with their matched
noncancer controls.4–6 It is estimated that 8% to 25% of all cancer survivors experience
depression; specifically, that 10% to 25% of breast cancer survivors,5,7,8 8% to 18% of
colorectal cancer (CRC) survivors,9,10 and 5% to 10% of prostate cancer survivors will
experience depression.11,12

Author Manuscript

Variability in the prevalence rates of depression may be due to heterogeneous samples and/or
differences in settings, time periods, and instruments that are used to diagnose depression.
Studies based on claims databases use the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) codes to identify depression.9–12 These studies
reported the lowest prevalence rates, followed by studies using the Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition (DSM-V) structured interview.7 Studies that use
the self-reported symptoms scales, such as the Beck Depression Inventory, with cutoff points
to diagnose depression have reported the highest prevalence rates of depression.7,8 For
example, the prevalence rate of depression among women with breast cancer was 6% based
on ICD-9-CM codes,5 11% (95% CI, 8%–16%) based on diagnostic interviews, and 20%
(95% CI, 16%–24%) based on self-reported symptoms scale.13
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Furthermore, the risk of newly diagnosed depression can be higher among cancer survivors
compared with age-and sex-matched noncancer cohorts. A retrospective cohort study
estimated that the incidence rate of depression among women with breast cancer was 2.4%,
and that women with breast cancer had a 58% higher risk of newly diagnosed depression
within a year after cancer diagnosis compared with their matched noncancer counterparts
(adjusted risk ratio [ARR], 1.58; 95% CI, 0.84–3.0).5
There are many reasons why patients with cancer may be at a higher risk of developing
depression compared with those without cancer. The cancer diagnosis itself may lead to
depression. For example, studies found that individuals diagnosed at an advanced stage have
a higher risk of developing depression compared with those diagnosed at an early
J Natl Compr Canc Netw. Author manuscript; available in PMC 2018 January 01.
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stage.5,14,15 Cancer treatment can also affect the risk of developing depression.
Retrospective studies among women with breast cancer reported a significant association
between chemotherapy treatment and the risk of depression.16–18 Among men with prostate
cancer, those who received androgen deprivation therapy or radiotherapy had a higher risk of
depression compared with those who underwent surgery.19–22 Cancer-related physical
symptoms such as pain, fatigue, and other physical limitations may lead to depression.
Cancer survivors who reported fatigue or pain had higher rates of depression than those who
did not report fatigue or pain.23–25

Author Manuscript

Moreover, the risk of newly diagnosed depression may be higher among some cancer types
compared with others due to differences in survival prognosis and stage at diagnosis.5,26 The
estimated 5-year relative survival rate is 65% for individuals with CRC compared with 89%
for women with breast cancer and 99% for men with prostate cancer.26 Danese et al5
reported that elderly women with breast cancer diagnosed at an advanced stage (stage IV)
had a higher risk of newly diagnosed depression compared with those diagnosed at an early
stage (stage I) (risk ratio [RR], 5.03; 95% CI, 3.45–7.35). CRC is more likely to be
diagnosed at an advanced stage and to have a poor survival prognosis compared with breast
and prostate cancers.5,26 Therefore, patients with CRC may have a higher risk of newly
diagnosed depression compared with those with breast or prostate cancers.
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Although the risk of newly diagnosed depression may vary by cancer type, there is a paucity
of research on the variations in the risk of newly diagnosed depression by cancer type.
Identifying cancer survivors, who are at high risk of newly diagnosed depression, is
important because depression can negatively affect health-related quality of life27 and
survival after cancer diagnosis.9,11,27 Depression among cancer survivors is also associated
with high healthcare utilization and expenditures compared with their counterparts without
depression.11,28–30 For example, elderly patients with both cancer and depression were more
likely to have emergency room visits, inpatient visits, outpatient visits, readmission, and
medication use compared with those without depression.11,28,29 Therefore, the objective of
this study was to examine variations in the risk of newly diagnosed depression among the
most common cancer types,26 with the following comparisons: women with breast cancer
compared with women with CRC, and men with prostate cancer compared with men with
CRC. These cancers were selected because they are the most common cancer types; breast
cancer among women (41%), prostate cancer among men (45%), and CRC among men and
women (8%).26
Conceptual Framework
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This study adapted the determinants-of-health model by Marmot and Wilkinson,31 which
posits that many dimensions affect an individual’s health or disease/illness (eg, newly
diagnosed depression). These dimensions are an individual’s physical make-up, social
support, access to care, health behaviors, psychological factors, biological risk factors,
treatment factors, community resources, and geographic region.

J Natl Compr Canc Netw. Author manuscript; available in PMC 2018 January 01.
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Methods
Data Source
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SEER-Medicare—This study used the linked SEER-Medicare files. The SEER Program is
an epidemiologic surveillance system consisting of population-based tumor registries
residing in 18 SEER areas.32 SEER cancer registries collect data on all incident cases of
cancer that occur in persons residing in SEER areas. These data are available in the Patient
Entitlement and Diagnosis Summary File (PEDSF), which has information on patient
demographic characteristics, cancer type, tumor characteristics, and chemotherapy and
radiation therapy provided within 4 months of cancer diagnosis. Because Medicare is the
primary health insurer for the elderly, SEER data have been linked to Medicare claims.
Medicare claims files consist of inpatient claims (Medicare Provider Analysis and Review),
outpatient claims (National Claims History files and outpatient claims files), and
prescription drug file.
American Community Survey Estimates From Census—This study used the
American Community Survey (ACS) 2008 to 2012 census tract and census zip code files.
We linked these files to PEDSF files by geographic codes, which included state and county.
We used these files to derive the census tract median household income and education level.

Author Manuscript

The Area Health Resource File—The Area Health Resource File (AHRF) is a publicly
available data file provided by the Department of Health & Human Services (DHHS), which
includes county, state, and national files.33 This study used the AHRF to provide countylevel urban/rural continuum codes, the presence of community mental health clinics
(CMHCs), and health professional shortage area of mental healthcare. We linked the AHRF
files to PEDSF files by geographic codes, which included state and county.
Study Design
This study used a retrospective cohort study design with a baseline and follow-up period. We
considered the date of cancer diagnosis as the index date. We defined the 12 months before
the index date as the baseline period and the 12 months after the index date as the follow-up
period.
Study Population

Author Manuscript

Identification of Cancer Survivors—The study population consisted of elderly patients
(age >65 years) with cancer who were diagnosed with primary-only incident breast, CRC,
and prostate cancers between 2007 and 2011. We imposed the age restriction of >65 years to
allow for a 12-month baseline period to identify chronic conditions and other risk factors
before cancer diagnosis. We identified the cancer types using the primary site variable and
the ICD-Oncology, Third Edition (ICD-O-3) histology codes.
Depression-Free Individuals at Cancer Diagnosis—We identified a depression-free
cohort among individuals with incident cancer. To ensure that the incident cancer cases were
depression-free, we used validated criteria from the National Committee for Quality
Assurance (NCQA).34 According to the NCQA, individuals are considered to be depression-

J Natl Compr Canc Netw. Author manuscript; available in PMC 2018 January 01.
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free at index date if they did not receive antidepressants 90 days before the index date (ie,
date of cancer diagnosis) or did not have a depression diagnosis 120 days before the index
date.
Other Inclusion/Exclusion Criteria—We required that all individuals have continuous
enrollment in Medicare Parts A and B and no enrollment in managed care plans during the
baseline and follow-up periods. To identify antidepressants 90 days before the index date,
we also required that individuals have continuous enrollment in Medicare Part D for 3
months before cancer diagnosis. We excluded individuals with an unknown stage at
diagnosis, diagnosed through autopsy or death certificate, and who died during the follow-up
period of 12 months. Supplemental eAppendix 1 illustrates the analytical population
selection process (available with this article at JNCCN.org).

Author Manuscript

Dependent Variable: Newly Diagnosed Depression (Yes/No)
The dependent variable was newly diagnosed depression after cancer diagnosis (newly
diagnosed depression) in breast, CRC, and prostate cancer survivors. To identify depression
diagnosis, we used a validated algorithm developed by the CMS Chronic Conditions Data
Warehouse.35 Individuals with at least one inpatient or outpatient visit with a depression
diagnosis during the 12-month follow-up period were classified as having newly diagnosed
depression. We identified the depression diagnosis using ICD-9-CM codes, which included
296.2 (major depressive disorder, single episode), 296.3 (major depressive disorder,
recurrent episode), 298.0 (depressive type psychosis), 300.4 (neurotic depression), 309.1
(prolonged depressive reaction), and 311.0 (depressive disorder, not classified). These codes
were widely used in previously published studies to identify depression diagnosis among
Medicare beneficiaries.11,36,37

Author Manuscript

Key Independent Variable
We selected the independent variables based on the determinants-of-health model. The key
independent variable was cancer type, which is considered a biological risk factor. Cancer
types were women with breast cancer, women with CRC, men with CRC, and men with
prostate cancer.
Other Independent Variables

Author Manuscript

Individual physical makeup variables included age in years at cancer diagnosis and race.
Social support included marital status. Access to care was measured by primary care
physician (PCP) visit quartiles, census tract median household income quartiles, and
percentage with a less than high school education level quartiles. Health behavior consisted
of tobacco use. Psychological factors included the presence of anxiety. Biological risk
factors were cancer stage at diagnosis (based on the AJCC) and chronic physical conditions.
Chronic conditions categories included cardiovascular disease (heart disease, diabetes,
hyperlipidemia, hypertension, stroke), respiratory disease (asthma, chronic obstructive
pulmonary disease), and musculoskeletal disease (arthritis, osteoporosis). These conditions
were selected based on the list of chronic conditions framework developed by DHHS
Multiple Chronic Conditions working group for research, planning, programs, and policy
purposes.38 We identified these conditions based on a validated algorithm developed by the
J Natl Compr Canc Netw. Author manuscript; available in PMC 2018 January 01.
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CMS Chronic Conditions Data Warehouse35: individuals had at least 1 inpatient or
outpatient visit during the baseline period. Treatment factors included cancer treatment
during the 6 months after cancer diagnosis, which included chemotherapy, radiation therapy,
and surgery. Cancer treatment was identified from claims data using the ICD-9-CM
Healthcare Common Procedure Coding System (HCPCS) and the Common Procedural
Terminology (CPT) codes. Community resources consisted of the presence or absence of
county-level CMHCs and whether the county of residence was designated as a health
professional shortage area for mental health. Geographical location consisted of the SEER
region and county metropolitan status, which was defined using 2013 urban/rural continuum
codes from the US Department of Agriculture’s Economic Research Service. To control for
changes in patterns of diagnosis over time, year of cancer diagnosis was also included as an
independent variable.

Author Manuscript

Statistical Analysis

Author Manuscript

We used chi-square tests to test the significance of unadjusted differences in baseline
characteristics and newly diagnosed depression. We used complementary log-log regression
analysis to examine the adjusted associations between cancer types and risk of newly
diagnosed depression with 4 different models. In Model 1, we included only cancer types
without controlling for other factors. In Model 2, we controlled for individual physical
make-up (eg, age, race) and social support. In Model 3, we additionally controlled for access
to care, health behaviors, biological risk factors (stage at cancer diagnosis and chronic
physical conditions), and psychological factors. In Model 4, we controlled for cancer
treatment factors, county-level community resources, geographic region, the year at cancer
diagnosis, and all other risk factors in Model 3 (age, race, marital status, PCP visits, median
household income, education level, tobacco use, anxiety, cancer severity measured by stage
at diagnosis, and chronic physical conditions). All statistical analyses were carried out using
SAS 9.4 (SAS Institute Inc., Cary, NC).

Results
Characteristics of the Study Population

Author Manuscript

The study population consisted of 53,821 elderly fee-for-service Medicare beneficiaries with
incident breast, CRC, or prostate cancer who were depression-free at the time of cancer
diagnosis. In the study population, 36.4% were women with breast cancer, 12.5% were
women with CRC, 9.5% were men with CRC, and 41.6% were men with prostate cancer
(data not shown in tabular form). Most of the study population was white (80.7%) and lived
in metropolitan areas (81%). We also found that 51.0% of the counties had a shortage of
mental health professionals and 48.9% did not have CMHCs (Table 1).
Cancer Types and Newly Diagnosed Depression
Overall, 3.3% of elderly Medicare patients with breast, CRC, and prostate cancer had newly
diagnosed de pression during the follow-up year. A chi-square analysis showed that newly
diagnosed depression rates significantly differed by cancer type (P<.001) (Table 2). We
found a significantly higher percentage of newly diagnosed depression among women with
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CRC compared with those with breast cancer (5.8% vs 3.9%), and among men with CRC
compared with those with prostate cancer (3.4% vs 1.6%).
Table 3 displays the RRs and ARR of newly diagnosed depression by cancer types from
multivariable complementary log-log regression analyses. In Model 1, which included only
cancer types, women with CRC had a 53% higher risk of newly diagnosed depression (RR,
1.53; 95% CI, 1.36–1.73) compared with women with breast cancer; men with CRC had a
111% higher risk of newly diagnosed depression (ARR, 2.12; 95% CI, 1.74–2.57) compared
with men with prostate cancer. This association between cancer type and risk of newly
diagnosed depression persisted in Models 2 to 4, even after controlling for all the risk factors
and the year at cancer diagnosis in the final model.
Sex and Newly Diagnosed Depression
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We found a significantly higher percentage of newly diagnosed depression among women
with CRC compared with men with CRC (5.8% vs 3.4%). In the adjusted analyses, we
found that women with CRC had a 46% higher risk of newly diagnosed depression
compared with men with CRC (ARR, 1.46; 95% CI, 1.22–1.76) (Table 4).
Cancer Stage and Newly Diagnosed Depression
We found that the risk of newly diagnosed depression was higher among cancer survivors
diag nosed at an advanced stage compared with those diagnosed at an early stage. For
example, cancer survivors diagnosed at stage IV had a 63% higher risk of newly diagnosed
depression compared with those diagnosed at stage I (ARR, 1.63; 95% CI, 1.31–2.03). The
RR and ARR of newly diagnosed depression by other variables are displayed in
supplemental eAppendix 2.
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Discussion

Author Manuscript

This is the first study to date that has evaluated the relationship between cancer type and risk
of newly diagnosed depression after cancer diagnosis among elderly individuals with
incident breast, CRC, and prostate cancer. In our study, the rate of newly diagnosed
depression was highest (5.8%) among women with CRC and lowest (1.6%) among men with
prostate cancer. Among women with breast cancer the rate of newly diagnosed depression
was 3.9% in our study, which is higher than the estimate (2.4%) available from published
literature.5 The higher incidence of depression among women with breast cancer in our
study may be due to differences in observation years, because it has been reported that the
percentage of diagnosed depression among elderly Medicare beneficiaries increases over
time.39 Additionally, although Danese et al5 used data from 1998–2002, the current study
used data from 2007–2012. We were not able to compare the incidence of depression for
CRC and prostate cancer found in our study with other studies, because there are no
published studies.
We found that the risk of newly diagnosed depression varied by cancer type. Women with
CRC had a higher risk of newly diagnosed depression compared with those with breast
cancer, even after adjustments for a comprehensive list of risk factors. Similarly, men with
CRC had a higher risk of newly diagnosed depression compared with those with prostate
J Natl Compr Canc Netw. Author manuscript; available in PMC 2018 January 01.
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cancer. As stated in the introduction, it is plausible that poor survival prognosis may have
increased the risk of depression among CRC survivors. This study also found that women
with CRC had a 52% higher risk of newly diagnosed depression compared with men with
CRC. This finding confirmed sex differences in the risk of depression that have been
documented previously.39 We also found in multivariable analyses that advanced stage at
cancer diagnosis was associated with a higher risk of newly diagnosed depression compared
with early stage at cancer diagnosis. This finding is consistent with prior published studies
documenting that advanced stage at cancer diagnosis is associated with a high risk of
depression.4,5
Clinical Practice and Policy Implications

Author Manuscript

Findings from our study have clinical practice and policy implications; they suggest that
healthcare providers need to screen for depression, especially among individuals with CRC
and those diagnosed with an advanced cancer stage. Because cancer is a dominant condition
and most of the care is usually directed toward treating cancer, such screening is important
to diagnose depression before it becomes severe. PCPs can play an important role in
detection and treatment of depression among cancer survivors. A national survey of
physicians conducted by the Cancer Care Outcomes Research & Surveillance Consortium
reported that PCPs are more involved in detection and treatment of depression in patients
with cancer compared with oncologists (50% vs 18%, respectively).40 Therefore, it is
important that oncologists and PCPs work together to identify and treat depression among
cancer survivors, because depression can negatively affect the health-related quality of life
and survival after cancer diagnosis.9,11,27

Author Manuscript

Communication between oncologists and PCPs can be improved by the use of survivorship
care plans, integrated collaborative care programs, use of electronic health records, and
training PCPs in cancer care. ASCO considers survivorship care plans, which consist of a
treatment summary and a follow-up plan, to be an essential component in survivorship care,
because they can enhance care coordination and communication between oncologists, PCPs,
and mental healthcare providers.41 One study reported that the communication of
survivorship care plans to PCPs was associated with better care coordination.42
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Collaborative care programs are one approach to integrating PCPs in cancer care to provide
screening, monitoring, and treatment of depression. For example, the integrated
collaborative care model, SMaRT Oncology-2 trial (Symptom Management Research Trial
in Oncology-2), found that collaborative care between oncologists, PCPs, and trained nurses
was associated with a significantly higher improvement in depression compared with the
usual care.43 Communication between oncologists and PCPs can also be improved by the
use of electronic health records and the training of PCPs in cancer care. It has been reported
that use of electronic medical records and PCP training in cancer care improved
communication and cancer care coordination between oncologists and PCPs.44,45
Study Strengths and Limitations
This study’s findings need to be interpreted in the context of its advantages and limitations.
One advantage is that this study used linked cancer registry and claims data, which allowed
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us to follow a large cohort of patients across a variety of health providers. Another
advantage is that we also controlled for a comprehensive list of factors, such as cancer stage
and treatment. This study also has some limitations. Because the study population was
restricted to fee-for-service Medicare beneficiaries and those residing in SEER regions, the
study findings are not generalizable to all Medicare beneficiaries. The focus of this study
was on the most common types of cancer; future studies may need to investigate the risk of
newly diagnosed depression and depression treatment rates among elderly patients with
other types of cancer. It is plausible that depression may be underrecognized and we may
have underestimated the rate of newly diagnosed depression.

Conclusions

Author Manuscript

This study has provided new evidence that there is variation in the risk of newly diagnosed
depression by cancer type. Healthcare providers of cancer survivors may need to routinely
screen individuals at high risk for depression, specifically those with CRC and those with an
advanced stage of cancer at diagnosis.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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a
Based on 53,821 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal, and prostate cancers who were continuously enrolled in Medicare Part A and B during the observation
period and who were alive during the observation period. Asterisks represent significant differences in newly diagnosed depression by cancer types, derived from complementary log-log regression.

Abbreviations: ARR, adjusted risk ratio; RR, risk ratio.
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enrolled in Medicare Part A and B during the observation period and who were alive during the observation period. Asterisks represent significant
differences in newly diagnosed depression by cancer types, derived from complementary log-log regression.
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